Published in Cancer Imaging on September 23, 2013
Point-of-care and point-of-procedure optical imaging technologies for primary care and global health. Sci Transl Med (2014) 1.08
Incorporating prognostic imaging biomarkers into clinical practice. Cancer Imaging (2013) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res (2009) 3.01
Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys (2004) 2.93
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood (2005) 2.92
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol (2001) 2.91
Sodium iodide symporter: its role in nuclear medicine. J Nucl Med (2002) 2.69
Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 2.67
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol (2005) 2.65
Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet (2002) 2.38
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 2.35
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol (2006) 2.31
Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging (2012) 2.31
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2013) 2.27
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging (2003) 2.25
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol (2004) 2.22
Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia (2005) 2.17
Positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol (2013) 2.05
Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology (2012) 2.00
Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2008) 1.95
Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol (1999) 1.95
Assessing tumor response to therapy. J Nucl Med (2009) 1.95
Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res (2009) 1.89
Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med (2002) 1.87
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol (2005) 1.84
Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology (2011) 1.84
The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med (2012) 1.84
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med (2005) 1.81
Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med (2009) 1.75
18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med (2007) 1.75
Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res (1993) 1.65
Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med (2011) 1.62
18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica (2006) 1.61
Multiparametric imaging of tumor response to therapy. Radiology (2010) 1.46
Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum (2008) 1.35
The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med (2005) 1.35
CT perfusion in oncologic imaging: a useful tool? AJR Am J Roentgenol (2013) 1.34
Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging (2008) 1.31
Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol (2006) 1.30
Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep (2005) 1.28
Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol (2009) 1.25
Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging (2009) 1.23
CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology (2007) 1.23
KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer (2010) 1.22
Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging (2008) 1.17
Molecular imaging of hypoxia. J Nucl Med (2011) 1.15
Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J Nucl Med (2006) 1.12
Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys (2008) 1.10
Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J Clin Oncol (2007) 1.10
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res (2005) 1.09
Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum (2011) 1.08
Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed (2010) 1.02
[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res (2011) 1.00
Blood flow-metabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res (2009) 0.97
Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med (2011) 0.97
99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med (2003) 0.93
Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg (2011) 0.93
Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography. Anticancer Res (2007) 0.90
68Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med (2004) 0.90
99mTc-MIBI in the evaluation of breast cancer biology. Eur J Nucl Med Mol Imaging (2004) 0.90
In vivo 1H MRS in the assessment of the therapeutic response of breast cancer patients. NMR Biomed (2011) 0.89
¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs. Eur J Nucl Med Mol Imaging (2012) 0.88
Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas. J Clin Pathol (2012) 0.87
Clinical imaging of tumor angiogenesis. Future Oncol (2012) 0.87
Response and progression-free survival in oropharynx squamous cell carcinoma assessed by pretreatment perfusion CT: comparison with tumor volume measurements. AJNR Am J Neuroradiol (2009) 0.86
18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. J Nucl Med (2012) 0.84
Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med (2010) 0.83
Response to treatment series: part 1 and introduction, measuring tumor response--challenges in the era of molecular medicine. AJR Am J Roentgenol (2011) 0.80
The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med (2001) 0.80
Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma. Cancer Biother Radiopharm (2004) 0.77
Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors. Br J Haematol (2001) 0.76
Combined (99m)Tc-methoxyisobutylisonitrile scintigraphy and fine-needle aspiration cytology offers an accurate and potentially cost-effective investigative strategy for the assessment of solitary or dominant thyroid nodules. Eur J Nucl Med Mol Imaging (2013) 2.95
Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging (2012) 2.31
Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.08
Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology (2012) 2.00
Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage. Cancer Imaging (2010) 1.98
Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology (2011) 1.84
Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med (2009) 1.75
Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. Radiology (2012) 1.46
Multiparametric imaging of tumor response to therapy. Radiology (2010) 1.46
Quantifying tumour heterogeneity with CT. Cancer Imaging (2013) 1.27
Texture analysis in non-contrast enhanced CT: impact of malignancy on texture in apparently disease-free areas of the liver. Eur J Radiol (2008) 1.16
¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging (2010) 1.00
In search of biologic correlates for liver texture on portal-phase CT. Acad Radiol (2007) 1.00
Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT. Eur J Nucl Med Mol Imaging (2008) 0.95
Helical CT in the diagnosis of acute lower gastrointestinal haemorrhage. Eur J Radiol (2006) 0.95
Hepatic enhancement in colorectal cancer: texture analysis correlates with hepatic hemodynamics and patient survival. Acad Radiol (2007) 0.88
Three-dimensional textural analysis of brain images reveals distributed grey-matter abnormalities in schizophrenia. Eur Radiol (2009) 0.86
Three-dimensional selective-scale texture analysis of computed tomography pulmonary angiograms. Invest Radiol (2008) 0.84
Integrated 18F-fluorodeoxyglucose-positron emission tomography/dynamic contrast-enhanced computed tomography to phenotype non-small cell lung carcinoma. Mol Imaging (2012) 0.82
Multidetector spiral CT renal angiography in the diagnosis of giant renal artery aneurysms. Abdom Imaging (2007) 0.81
Staging of non-small-cell lung cancer with integrated PET and CT. N Engl J Med (2003) 0.78
Cancer imaging: quo vadis? Cancer Imaging (2014) 0.78
Concordance of 18F-FDG PET Uptake in Tumor and Normal Tissues on PET/MRI and PET/CT. Clin Nucl Med (2016) 0.77
Renal and hepatic kinetics of Tc-99m-labelled hexakis-methoxy-isobutyl Isonitrile. Drug Metab Lett (2012) 0.76
Incorporating prognostic imaging biomarkers into clinical practice. Cancer Imaging (2013) 0.75
Old tracer for a new purpose: potential role for 99mTc-2-Methoxyisobutylisonitrile (99mTc-MIBI) in renal transplant care. Nucl Med Commun (2014) 0.75